TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04992962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/CBN
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/THC
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive compound.
Study: NCT05848622

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real-time gait biofeedback
Description: The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham real-time gait biofeedback
Description: The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
Study: NCT04638582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
Study: NCT04921007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral ESP block
Description: A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
Study: NCT04586998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhaled drug monitor Edmon
Description: Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
Study: NCT05581979

Intervention type: DIAGNOSTIC_TEST
Intervention: 68-Ga PSMA PET scan
Description: On the scheduled visit date for the study,~* An intravenous cannula (plug) will be inserted in a vein in the participant's arm, through which the 68-Ga PSMA radiotracer for the scan will be injected. The infusion will take about 1-2 minutes.~* PET imaging will be performed with a dedicated PET/CT scanner. 2.5-6.0 mCi (depending on weight of the patient) of PSMA radiotracer will be injected intravenously.
Study: NCT06190795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMPLIFY Smartphone Application
Description: AMPLIFY Smartphone Application enables prescription and progression of exercises/functional activities, while offering immediate feedback on upper limb movement performed, real-time logging and monitoring of adherence through virtual platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hardcopy Manual
Description: Hardcopy Manual
Study: NCT06227208

Intervention type: DEVICE
Intervention: Continuous vital sign monitoring
Description: Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.

Intervention type: DEVICE
Intervention: Continuous vital sign monitoring
Description: Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.

Intervention type: DEVICE
Intervention: Continuous vital sign monitoring
Description: Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
Study: NCT04464265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze.
Study: NCT05474066

Intervention type: DEVICE
Intervention: ERP Testing
Description: * Attention \& Concentration:~* Continuous Visual Memory Test (CVMT):~* Flanker Task:~* Hayling Test:
Study: NCT06166979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Study Group A: Blis Q24 Serum at higher dose
Description: Active Comparator: Study Group A: Blis Q24 Serum at 1e8 cfu/ dose (Active)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Study Group B: Blis Q24 Serum at lower dose
Description: Active Comparator: Study Group A: Blis Q24 Serum at 1e6 cfu/ dose (Active)
Study: NCT04638517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Danazol up to 800mg daily in two-divided doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study: NCT05742503

Intervention type: OTHER
Intervention: Depo-Provera
Description: Injectable progesterone

Intervention type: OTHER
Intervention: Implanon
Description: Etonogestrel implant

Intervention type: OTHER
Intervention: Norgestrel
Description: Pill containing progesterone

Intervention type: OTHER
Intervention: Mirena
Description: Levonorgestrel-releasing intra-uterine drug (IUD)
Study: NCT05398887

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low radiation dose CT
Description: Underwent low dose chest CT with 30% lower radiation dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Underwent ultra dose chest CT
Description: Underwent ultra dose chest CT with 90% lower radiation dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence based model
Description: Deep-learning based contrast boosting algorithms
Study: NCT06435754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group Vestibular Socket Preservation
Description: After atraumatic extraction Vestibular access horizontal incision will be made at the socket site, at the mucco-buccal fold. Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group ice cream cone technique
Description: After atraumatic extraction Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
Study: NCT05082116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol (N8-GP)
Description: N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
Study: NCT06296745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
Study: NCT05192304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet
Study: NCT05915897

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: blood donation
Study: NCT05793177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday Life is Rehabilitation
Description: Behavior change intervention focuses on implementing more movement into everyday life using action planning, goal setting, and fatigue management.
Study: NCT06102577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1gr. Vitamine C
Description: Take 1g. of vitamin C at the end of an osteopathic manual treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1gr Placebo
Description: ake 1g. of placebo at the end of an osteopathic manual treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: control
Study: NCT04970043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+ pemetrexed + platinum
Description: Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.~Maintenance treatment period:~Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years).
Study: NCT05223751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meo Health Breathing and humming exercises
Description: The Intervention Group will receive training on the Meo Health breathing therapy, which will include:~* Being shown the Meo Health Breathing Therapy On-Boarding video~* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.~* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.~Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.~A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.~A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group.
Study: NCT05432869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ES and lifestyle advices
Description: The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.~External electrical stimulation will be applied for 30 minutes 3 days a week during 4 weeks. Electrodes were placed on the thighs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle advices
Description: The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.
Study: NCT06159192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shock wave
Description: Extracorporeal shock wave therapy generator: Wonjin beauty SW10 shock wave therapy system made in Korean.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shock wave
Description: Extracorporeal shock wave therapy generator: Wonjin beauty SW10 shock wave therapy system made in Korean.
Study: NCT06418438

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic uterosacral ligament suspension with hysterectomy
Description: After anesthesia, bladder stone removal patients undergo laparoscopic hysterectomy. The adnexa are coagulated and cut, and the bladder peritoneal reflection is opened. The uterus is removed transvaginally. Next, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the residual end.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterosacral ligament suspension with cervical amputation
Description: After anesthesia, bladder stone removal patients undergo cervical amputation surgery. The cervix is exposed and elevated using Allis forceps. A dilator is used to expand the cervix, and an incision is made on the anterior vaginal wall. The cervix is excised and shaped using the Sturmdorf method. Afterward, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the uterus.
Study: NCT05651932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A1 & A2
Description: KTX-1001 will be administered orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort C1 & C2
Description: KTX-1001: Orally for 28 days each cycle until progression Carfilzomib: IV, once weekly for 3 weeks in each 28-day cycle Dexamethasone: Orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort D
Description: KTX-1001: Orally daily for 28 days each cycle until progression Pomalidomide: Orally, for 21 days in each 28-day cycle Dexamethasone: Orally once a week
Study: NCT06132854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: The virtual environment is provided by the Oculus Quest 2 or 3 VR headset, providing a high-quality and immersive visual experience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet
Description: Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure.
Study: NCT05169125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard hemodialysis
Description: patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lower dialysate sodium dialysis
Description: patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L)
Study: NCT05182996

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smoking education
Description: Educate on the relationship between inflammatory bowel disease and smoking and the necessity and importance of quitting smoking.
Study: NCT05055414

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UI030
Description: Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI030
Description: Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
Study: NCT05543655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fidelity simulation
Description: Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing.
Study: NCT06249945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
Study: NCT06101823

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OpSCF
Description: Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OpSCF
Description: Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer without active agent

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OpSCF (Open Label Extension)
Description: Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
Study: NCT05830578

Intervention type: DEVICE
Intervention: ASUS Blood Pressure Monitor/Oximeter/ECG Monitor
Description: The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result.

Intervention type: DEVICE
Intervention: ASUS Blood Pressure Monitor/Oximeter/ECG Monitor
Description: The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result.